Do analysts rate SYBX or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SYBX or BCTX more profitable?

Synlogic's return on equity of -26.47% beat Briacell Therap's return on equity. Company Net Margins Return on Equity Return on Assets Synlogic N/A -26.47% -18.00% Briacell Therap N/A -153.53% -129.26%

Do analysts recommend SYBX or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 1,150.00%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate DARE or SYBX?

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 719.67%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Dare Bioscience is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or SYBX more profitable?

Dare Bioscience's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Synlogic N/A -26.47% -18.00%

Do analysts rate BGM or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BGM or SYBX?

BGM Group has higher revenue and earnings than Synlogic. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.75 -$1.44M N/A N/A Synlogic $8K 1,044.69 -$23.36M -$0.06 N/A

Is BGM or SYBX more profitable?

BGM Group's return on equity of 0.00% beat Synlogic's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Synlogic N/A -26.47% -18.00%

Do analysts prefer SNTI or SYBX?

Senti Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 2,241.92%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNTI or SYBX more profitable?

Synlogic's return on equity of -26.47% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Synlogic N/A -26.47% -18.00%

Synlogic (SYBX) Competitors

$0.71 +0.00 (+0.49%)

As of 10:36 AM Eastern

Compare

SYBX vs. BCTX, BTAI, DARE, BGM, and SNTI

Should you buy Synlogic stock or one of its competitors? MarketBeat compares Synlogic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synlogic include Briacell Therap (BCTX), BioXcel Therapeutics (BTAI), Dare Bioscience (DARE), BGM Group (BGM), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry.

How does Synlogic compare to Briacell Therap?

Synlogic (NASDAQ:SYBX) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Synlogic has higher revenue and earnings than Briacell Therap. Synlogic is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,044.69	-$23.36M	-$0.06	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synlogic has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Synlogic's return on equity of -26.47% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Briacell Therap	N/A	-153.53%	-129.26%

63.4% of Synlogic shares are owned by institutional investors. Comparatively, 15.4% of Briacell Therap shares are owned by institutional investors. 2.6% of Synlogic shares are owned by insiders. Comparatively, 0.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Synlogic's average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.

Company	Overall Sentiment
Synlogic	Neutral
Briacell Therap	Neutral

Summary

Synlogic beats Briacell Therap on 7 of the 9 factors compared between the two stocks.

How does Synlogic compare to BioXcel Therapeutics?

Synlogic (NASDAQ:SYBX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 1,150.00%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

63.4% of Synlogic shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 2.6% of Synlogic shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Synlogic has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Synlogic has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Synlogic has higher earnings, but lower revenue than BioXcel Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8K	1,044.69	-$23.36M	-$0.06	N/A
BioXcel Therapeutics	$640K	42.46	-$69.90M	-$5.75	N/A

In the previous week, Synlogic's average media sentiment score of 0.00 equaled BioXcel Therapeutics'average media sentiment score.

Company	Overall Sentiment
Synlogic	Neutral
BioXcel Therapeutics	Neutral

Summary

Synlogic and BioXcel Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Synlogic compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Dare Bioscience has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	17.86	-$13.40M	-$0.95	N/A
Synlogic	$8K	1,044.69	-$23.36M	-$0.06	N/A

Dare Bioscience's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Synlogic	N/A	-26.47%	-18.00%

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 2.6% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 719.67%. Given Dare Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Dare Bioscience is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Dare Bioscience had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Dare Bioscience and 0 mentions for Synlogic. Dare Bioscience's average media sentiment score of 0.23 beat Synlogic's score of 0.00 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Neutral
Synlogic	Neutral

Dare Bioscience has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

Summary

Dare Bioscience beats Synlogic on 11 of the 15 factors compared between the two stocks.

How does Synlogic compare to BGM Group?

BGM Group (NASDAQ:BGM) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

BGM Group has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

63.4% of Synlogic shares are held by institutional investors. 58.7% of BGM Group shares are held by company insiders. Comparatively, 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BGM Group's return on equity of 0.00% beat Synlogic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Synlogic	N/A	-26.47%	-18.00%

In the previous week, BGM Group's average media sentiment score of 0.00 equaled Synlogic'saverage media sentiment score.

Company	Overall Sentiment
BGM Group	Neutral
Synlogic	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has higher revenue and earnings than Synlogic.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.75	-$1.44M	N/A	N/A
Synlogic	$8K	1,044.69	-$23.36M	-$0.06	N/A

Summary

BGM Group beats Synlogic on 6 of the 8 factors compared between the two stocks.

How does Synlogic compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Senti Biosciences has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Synlogic has lower revenue, but higher earnings than Senti Biosciences. Synlogic is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	665.05	-$61.44M	-$1.92	N/A
Synlogic	$8K	1,044.69	-$23.36M	-$0.06	N/A

Senti Biosciences presently has a consensus price target of $10.00, indicating a potential upside of 2,241.92%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synlogic's return on equity of -26.47% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Synlogic	N/A	-26.47%	-18.00%

In the previous week, Senti Biosciences' average media sentiment score of 0.23 beat Synlogic's score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Neutral
Synlogic	Neutral

Summary

Senti Biosciences beats Synlogic on 9 of the 15 factors compared between the two stocks.

Get Synlogic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYBX vs. The Competition

Export

Metric	Synlogic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.36M	$3.66B	$6.84B	$12.29B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-2.75	21.60	26.83	23.84
Price / Sales	1,044.69	304.44	578.88	114.27
Price / Cash	N/A	155.65	50.60	60.45
Price / Book	0.66	7.99	10.19	6.09
Net Income	-$23.36M	$23.81M	$3.60B	$331.73M
7 Day Performance	-2.52%	-1.61%	-1.89%	-1.74%
1 Month Performance	2.09%	-1.66%	-0.77%	-3.01%
1 Year Performance	-55.34%	34.39%	18.89%	14.19%

Synlogic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYBX Synlogic	N/A	$0.71 +0.5%	N/A	-55.6%	$8.36M	$8K	N/A	80
BCTX Briacell Therap	0.3699 of 5 stars	$3.94 +6.5%	N/A	-55.3%	$32.19M	N/A	N/A	8	Positive News
BTAI BioXcel Therapeutics	2.163 of 5 stars	$0.92 -10.5%	$11.00 +1,093.7%	-51.3%	$31.80M	$680K	N/A	90
DARE Dare Bioscience	2.3134 of 5 stars	$2.07 flat	$10.00 +383.1%	-53.3%	$31.01M	$1.03M	N/A	30	News Coverage
BGM BGM Group	0.6883 of 5 stars	$0.31 -0.4%	N/A	-97.2%	$30.35M	$25.10M	N/A	298	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYBX) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synlogic (SYBX) Competitors

SYBX vs. BCTX, BTAI, DARE, BGM, and SNTI

How does Synlogic compare to Briacell Therap?

Summary

How does Synlogic compare to BioXcel Therapeutics?

Summary

How does Synlogic compare to Dare Bioscience?

Summary

How does Synlogic compare to BGM Group?

Summary

How does Synlogic compare to Senti Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synlogic (SYBX) Competitors

SYBX vs. BCTX, BTAI, DARE, BGM, and SNTI

How does Synlogic compare to Briacell Therap?

Which has better valuation & earnings, SYBX or BCTX?

Do analysts rate SYBX or BCTX?

Which has more volatility and risk, SYBX or BCTX?

Is SYBX or BCTX more profitable?

Do insiders & institutionals hold more shares of SYBX or BCTX?

Does the media refer more to SYBX or BCTX?

Summary

How does Synlogic compare to BioXcel Therapeutics?

Do analysts recommend SYBX or BTAI?

Do institutionals and insiders hold more shares of SYBX or BTAI?

Is SYBX or BTAI more profitable?

Which has more risk & volatility, SYBX or BTAI?

Which has preferable valuation and earnings, SYBX or BTAI?

Does the media favor SYBX or BTAI?

Summary

How does Synlogic compare to Dare Bioscience?

Which has higher earnings and valuation, DARE or SYBX?

Is DARE or SYBX more profitable?

Do insiders and institutionals have more ownership in DARE or SYBX?

Do analysts rate DARE or SYBX?

Does the media prefer DARE or SYBX?

Which has more volatility & risk, DARE or SYBX?

Summary

How does Synlogic compare to BGM Group?

Which has more volatility & risk, BGM or SYBX?

Do insiders & institutionals have more ownership in BGM or SYBX?

Is BGM or SYBX more profitable?

Does the media refer more to BGM or SYBX?

Do analysts rate BGM or SYBX?

Which has preferable earnings & valuation, BGM or SYBX?

Summary

How does Synlogic compare to Senti Biosciences?

Which has more volatility & risk, SNTI or SYBX?

Do institutionals & insiders believe in SNTI or SYBX?

Which has preferable valuation & earnings, SNTI or SYBX?

Do analysts prefer SNTI or SYBX?

Is SNTI or SYBX more profitable?

Does the media prefer SNTI or SYBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYBX vs. The Competition

Synlogic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools